Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Merck & Co. Inc.
Headquarters: Rahway, NJ, United States of America
Website: https://www.merck.com/
Year Founded: 1891
Status: Public
Industry Sector: HealthTechnology
CEO: Robert M. Davis, MBA
Number Of Employees: 75,000
Enterprise Value: $277,342,680,000
PE Ratio: 12.94
Exchange/Ticker 1: NYSE:MRK
Exchange/Ticker 2: N/A
Latest Market Cap: $220,068,610,048
BioCentury | Apr 1, 2025
Politics, Policy & Law
‘Pandemonium’ at FDA
Peter Stein pushed out as head of OND; thousands of layoffs
BioCentury | Apr 1, 2025
Deals
Novo, Merck each pay $200M for pipeline additions: Deals Report
Pharmas enter nine-figure upfront deals in metabolic, cardiovascular areas; plus, Bluebird will consider competing buyout offer
BioCentury | Apr 1, 2025
Product Development
Oral PCSK9 inhibition: Will co-formulation drive success?
AZ’s latest data position AZD0780 as slightly less effective but more convenient than PCSK9 competition
BioCentury | Mar 27, 2025
Data Byte
Immunology takeouts led by IgA nephropathy, IBD
Seven of 11 $1B+ immunology acquisitions focused on two diseases
BioCentury | Mar 26, 2025
Management Tracks
FDA names Barclay Butler COO
Plus: Scott Gottlieb named chair of Illumina, and updates from Syncromune and OSR
BioCentury | Mar 26, 2025
Finance
Early lessons from the NewCo Model
Panelists on a Capital Markets Preview webinar from BioCentury and Oppenheimer debate the hottest trend in dealmaking
BioCentury | Mar 26, 2025
Data Byte
China deals look beyond cancer
At least eight East-to-West licensing deals outside oncology so far this year
BioCentury | Mar 17, 2025
Finance
With Medicxi’s backing, Curevo takes aim at Shingrix with $110M series B
Former GSK vaccines head Slaoui becomes chairman as Seattle start-up advances shingles shot that may confer tolerability benefit
BioCentury | Mar 7, 2025
Finance
Strategics back Trimtech’s protein cluster degraders with $31M: Finance Report
Pharma venture arms join founding investors CIC, DDF to back U.K. start-up; plus venture rounds for Garuda, Ataraxis and Callio, and Tenaya’s follow-on
Items per page:
1 - 10 of 10931